araag2/HINT huggingface dataset:
Clinical trial NCT01110785 (phase 2, status: unknown status)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: simvastatin
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of colorectal cancer

               -  Advanced or metastatic disease

          -  Failed prior fluorouracil-, oxaliplatin- and irinotecan-containing regimens

               -  In case of progressive disease within 6 months after start of adjuvant
                  fluorouracil-, oxaliplatin-, and irinotecan-containing regimens, the adjuvant
                  therapy is considered to be treatment for metastatic disease

          -  Mutant-type k-ras status (mutation in codon 12, 13, or 61) on tumor material

          -  Measurable disease according to RECIST criteria version 1.1

          -  Progressive disease in the past 3 months according to RECIST criteria version 1.1

          -  No symptomatic brain metastases, defined as any symptoms during the past 6 months

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  WBC ≥ 2.0 x 10^9/L

          -  ANC ≥ 1.5 x 10^9/L

          -  Platelet count ≥ 100 x 10^9/L

          -  Hemoglobin ≥ 9 g/dL

          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST/ALT ≤ 3 times ULN (≤ 5 times ULN in case of liver metastases)

          -  Creatinine clearance ≥ 60 mL/min

          -  Magnesium normal

          -  Calcium normal

          -  Creatine phosphokinase ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Not planning to become pregnant within 6 months after the end of study treatment

          -  Fertile patients must use highly effective contraception during and for 6 months after
             completion of study therapy

          -  No noncompliance in previous studies

          -  No alcohol use > 4 units/day or unwilling to abstain from use

          -  No history of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or
             signs of interstitial lung disease on baseline CT scan

          -  No clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, or serious uncontrolled cardiac
             arrhythmia) < 1 year prior to study

          -  No symptomatic hypothyroidism

          -  No history of toxicity during statin use

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior EGFr-therapy, including monoclonal antibodies (e.g., panitumumab or
             cetuximab)

          -  No concurrent verapamil, amiodarone, or dronedarone or unwilling to abstain from use
Clinical trial NCT00331006 (phase 2, status: completed)
Conditions: hemophilia a
ICD codes: Z14.01, Z14.02, D68.311
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Severe congenital hemophilia A

          -  Documented historical inhibitor titer to factor VIII of at least 5 BU/mL

          -  Inhibitor level greater than or equal to 5 BU/mL 5 to 14 days after initial factor
             VIII exposure during screening

        Exclusion Criteria:

          -  Known hypersensitivities or allergies to murine and/or humanized antibodies

          -  Currently participating in investigational hemophilia studies

          -  HIV infected

          -  Any immunodeficiency disorder

          -  Liver disease and serum ALT or AST is greater than three times the upper limit of
             normal, albumin is less than 2.5g/dl, and/or INR is greater than 1.7

          -  Received interferon or other immunomodulatory drugs, such as steroids or cytotoxic
             therapy in the 30 days prior to study entry

          -  History of cardiac arrhythmias, any active febrile illness, kidney insufficiency, or
             pulmonary infiltrates

          -  Has previously received rituximab treatment

          -  Currently undergoing immune tolerance therapy

          -  Evidence of Hepatitis B (HBV) infection, defined as one of the following:

               -  HBsAg positive

               -  HBsAg negative, HBsAb negative, HBcAb positive, and HBV DNA positive

          -  Participants with a high responding inhibitor (at least 5 BU/mL) first detected fewer
             than 12 months prior to study entry, unless the participant has failed immune
             tolerance therapy, defined as one of the following:

               1. Failure to fulfill the criteria for full or partial success within 33 months, as
                  defined by a factor VIII recovery greater than or equal to 66% of expected and
                  half-life greater than or equal to 6 hours measured after a 72-hour
                  treatment-free washout period

               2. Failure to achieve greater than 20% reduction in inhibitor titer during each
                  interim non-overlapping 6-month period of ITT in the absence of documented
                  infection, with 9 months as the minimum treatment period and 33 months as the
                  maximum possible duration of unsuccessful ITT

               3. Withdrawal from ITT for any other reason

          -  Routinely receive factor VIII concentrate for the treatment of both major and minor
             bleeding events

          -  Has received factor VIII concentrate in the 7 days prior to study entry
Clinical trial NCT00543569 (phase 2, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: alefacept, tacrolimus, basiliximab, mycophenolate mofetil, corticosteroids
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is anticipated to receive first oral dose of tacrolimus within 48 hours of
             transplant procedure

          -  Subject is a recipient of a de novo kidney transplant

          -  Subject is a recipient of a kidney from a non-human leukocyte antigen (HLA) identical
             related living donor, a non-related living donor, or a deceased donor

        Exclusion Criteria:

          -  Subject has a screening (pre-operative)estimated cluster of differentiation (CD) 4+
             T-cell count of < 250 cells/µL

          -  Subject will receive a kidney with an anticipated cold ischemia time (CIT) of > 30
             hours

          -  Recipient has a positive T or B-cell cross match by investigational site's standard
             method of determination

          -  Subject will receive a kidney from a 50-65 year old deceased donor with one of the
             following:

               -  History of hypertension and a terminal serum creatinine > 1.5 mg/dL

               -  Cerebrovascular accident as cause of death and a terminal serum creatinine > 1.5
                  mg/dL

               -  History of hypertension and cerebrovascular accident as cause of death and a
                  terminal serum creatinine > 1.5 mg/dL
Clinical trial NCT00727194 (phase 2, status: terminated)
Conditions: myasthenia gravis
ICD codes: P94.0, G70.00, G70.01
Drugs: eculizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Generalized MG

          -  MGFA Clinical Classification Class II, III or IVa.

          -  QMG total score ≥12

          -  Minimum score of two (2) in four (4) or more test items in the QMG

          -  Able to give informed consent.

          -  Have failed at least two immunosuppressants after one year of treatment

          -  A positive serologic test for binding anti-acetylcholine receptor Abs at Screening and
             one of the following a) history of abnormal neuromuscular transmission test
             demonstrated by single-fiber electromyography or repetitive nerve stimulation, or b)
             history of positive anticholinesterase test, eg, edrophonium chloride test, or c)
             patient has demonstrated improvement in MG signs on acetylcholinesterase inhibitors as
             assessed by treating physician.

        Exclusion Criteria:

          -  History of thymoma or other neoplasms of the thymus.

          -  History of thymectomy within 12 months prior to screening.

          -  Pregnancy or lactation

          -  Current or chronic use of plasmapheresis/plasma exchange

          -  IVIG treatment within 8 weeks prior to screening.

          -  Use of etanercept within 2 months prior to screening.

          -  Use of rituximab (RITUXAN®) within 6 months prior to screening.

          -  MGFA Class I, IVb, and V

          -  Crisis or impending crisis
Clinical trial NCT00106054 (phase 2, status: terminated)
Conditions: colorectal neoplasms, liver neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: combination therapy of irinotecan with 5-fu, leucovorin plus bevacizumab in the neoadjuvant setting.
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    after 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could be
    performed.
  
Eligibility criteria:

        Inclusion Criteria:

          -  ECOG performance status of 0 or 1

          -  Histological documentation of adenocarcinoma of the colon or rectum. The primary site
             must have been confirmed to be in the large bowel

        Exclusion Criteria:

          -  Prior systemic anticancer therapy for mCRC

          -  Prior hepatic surgery, chemoembolization, hepatic artery infusion, radiofrequency
             ablation or cryotherapy for liver metastases
Clinical trial NCT00331045 (phase 2, status: terminated)
Conditions: cancer, constipation
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: alvimopan, placebo, alvimopan 0.5 mg/day, alvimopan 1 mg/day
SMILES: C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1, C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1
Reason stopped: 
    subject registration did not proceed as expected; difficult to complete within scheduled time
    frame; prematurely terminated w/ 21 subjects randomized.
  
Eligibility criteria:

        Inclusion criteria:

          -  Have cancer.

          -  Taking opioid therapy for continued intractable pain.

          -  Experiencing less bowel movement frequency compared to that before the opioid
             treatment.

          -  Must meet the protocol-definition of opioid-induced constipation.

        Exclusion criteria:

          -  Gastrointestinal or pelvic disorders known to affect gastrointestinal functions or
             induce bowel transit disorder and ileus.

          -  Subjects, who in the investigator's opinion, have gastrointestinal dysfunction
             predominantly due to causes other than the use of opioids.
Clinical trial NCT00408603 (phase 2, status: completed)
Conditions: epithelial ovarian cancer
ICD codes: H18.523, H18.521, H18.522, H18.529
Drugs: voreloxin injection
SMILES: CN[C@H]1CN(C[C@@H]1OC)C1=CC=C2C(=O)C(=CN(C3=NC=CS3)C2=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically documented epithelial ovarian cancer, primary
             peritoneal carcinoma, or fallopian tube cancer

          -  Completed at least one Platinum Based Therapy (PBT) regimen (carboplatin, cisplatin,
             or another organoplatinum compound).

          -  Evidence of platinum-resistant disease, relapse/progression within 6 months of the
             completion of PBT, or intolerant to PBT (inability to receive PBT due to
             hypersensitivity reactions to platinum)

          -  Patients with primary platinum-resistant disease are allowed to receive no more than
             one nonplatinum cytotoxic regimen and no more than one noncytotoxic regimen for the
             management of recurrent or persistent disease after the development of primary
             platinum-resistance.

          -  Measurable disease per GOG-RECIST criteria

          -  GOG Performance Status of 0 or 1

        Exclusion Criteria:

          -  Radiotherapy, chemotherapy, and hormonal, cytokine, or targeted therapy, within 3
             weeks (nitrosurea or mitomycin C within 6 weeks) prior to the anticipated first day of
             treatment.

          -  Monoclonal antibody therapy within 4 weeks prior to clinical study entry

          -  Unresolved or impending bowel obstruction

          -  Other active malignancies or other malignancies within the last 12 months except
             nonmelanoma skin cancer or cervical intraepithelial neoplasia

          -  Prior radiotherapy to more than 25% of the marrow space

          -  Requiring hemodialysis or peritoneal dialysis

          -  Myocardial infarction or cerebrovascular accident/transient ischemic attack within the
             6 months prior to the anticipated first day of treatment

          -  Thromboembolic event (deep vein thrombosis [DVT] or pulmonary embolus [PE]) within 28
             days prior to the anticipated first day of treatment

          -  History of active CNS metastases

          -  Any other medical, psychological, or social condition that would contraindicate the
             patient's participation in the clinical study due to safety or compliance with
             clinical study procedures.

        Please note: There are additional inclusion/exclusion criteria for this study. Please
        contact the study center for additional information and to determine if you meet all study
        criteria.
Clinical trial NCT00553592 (phase 2, status: unknown status)
Conditions: diabetic peripheral neuropathy
ICD codes: A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, I73.9
Drugs: bicifadine, bicifadine, bicifadine
SMILES: CC1=CC=C(C=C1)C12CC1CNC2, CC1=CC=C(C=C1)C12CC1CNC2, CC1=CC=C(C=C1)C12CC1CNC2
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 years or older

          -  Diagnosis of type-1 or type 2 non-insulin dependent diabetes mellitus

          -  Chronic bilateral pain due to diabetic neuropathy

          -  Pain for at least six months

          -  Primary pain is located in the feet

          -  Others-contact site for information

        Exclusion Criteria:

          -  Symptoms of other painful conditions

          -  Presence of amputations other than toes

          -  Clinically significant psychiatric or other neurological disorder

          -  Use of certain medications

          -  Clinically important other diseases

          -  Pregnancy

          -  History of alcohol or narcotic abuse within two years

          -  Others-contact site for information
Clinical trial NCT00562952 (phase 2/phase 3, status: completed)
Conditions: diabetes mellitus, heart failure, coronary artery disease
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9, I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0, I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: telmisartan, bisoprolol, placebo
SMILES: CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18 years

          -  Known Diabetes mellitus > 6 months

          -  Increased Nt-proBNP above 125pg/ml

          -  Given informed consent

        Exclusion Criteria:

          -  Disease other than diabetes, with a life expectancy below 1 year

          -  patients who suffer from chronic infection or malignant disease

          -  Women in childbearing age without contraceptive

          -  History of cardiac disease

          -  systemic cortisone treatment

          -  patients who are on chronic or acute hemodialysis, ultra filtration or peritoneal
             dialysis
Clinical trial NCT00442832 (phase 2, status: completed)
Conditions: staphylococcal skin infection
ICD codes: G00.3, M00.09, A05.0, M00.08, L00, M00.00, M00.011
Drugs: td-1792, vancomycin
SMILES: CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  major abscess requiring surgical incision and drainage,infected burn, deep/extensive
             cellulitis, infected ulcer, wound infections

          -  requires at least 7 days of intravenous antibiotic treatment

        Exclusion Criteria:

          -  more than 24 hours of antibiotic therapy

          -  moderate or severe liver disease

          -  severely neutropenic

          -  baseline QTc > 500 msec, congenital long QT syndrome, uncompensated heart failure,
             uncorrected abnormal K+ or Mg++ blood levels or severe left ventricular hypertrophy
Clinical trial NCT00320541 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, paclitaxel, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Females diagnosed with breast cancer and the cancer has spread to distant areas of the
             breast or organs.

          -  Must be able to measure the disease by specific medical parameters

          -  May have received breast cancer treatment in the early stage of the disease

          -  May be restricted in physically strenuous activity but able to carry out light work.

          -  Must have adequate organ function as seen in blood test results.

        Exclusion

        Criteria:

          -  Cancer that has spread to the brain.

          -  Unstable heart problems

          -  Unstable high blood pressure.

          -  Breast cancer treatment after the disease has considered to spread to other areas or
             organs.

          -  Unable to agree with the requirements of the study
Clinical trial NCT00677248 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: ezetimibe and placebo, eprotirome and ezetimibe
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=CC(OC2=C(Br)C=C(NC(=O)CC(O)=O)C=C2Br)=CC=C1O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females aged 18 to 75 years

          -  Patient with primary hypercholesterolemia with an LDL-cholesterol > 3.0 mmol/L

          -  At randomization, diet as instructed by the investigator during the last 4 weeks prior
             to randomization and willingness to follow these instructions throughout the study

        Exclusion Criteria:

          -  History of somatic or psychiatric disease/condition, which may interfere with the
             objectives of the study
Clinical trial NCT01598103 (phase 2, status: terminated)
Conditions: neurogenic urinary bladder, neurogenic bladder disorder, neurogenic dysfunction of the urinary bladder, neurogenic bladder, uninhibited, neurogenic bladder, spastic
ICD codes: G98.0, K59.2, M48.061, M48.062
Drugs: saf312, placebo to saf312
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with neurogenic detrusor overactivity due to spinal cord lesions

          -  Patients are inadequately managed by antimuscarinic medication and present with a
             cystometric bladder capacity of max. 400 mL

        Exclusion Criteria:

          -  Chronic inflammation such as interstitial cystitis, bladder stones, hematuria of
             unknown origin, previous pelvic radiation therapy or previous or current malignant
             disease of the pelvic organs

          -  Pelvic or genitourinary tract anomalies including surgery or bladder disease other
             than detrusor overactivity impacting on bladder function
Clinical trial NCT01598415 (phase 2, status: completed)
Conditions: knee osteoarthritis
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: sar113945, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria :

        Diagnosis of primary knee osteoarthritis, based upon the following:

          -  X-ray or Magnetic Resonance Imaging (MRI) evidence within the last 6 months for joint
             space narrowing and osteophyte formation

          -  Patients will be Kellgren and Lawrence classification II/III, and total Western
             Ontario McMaster (WOMAC) score 24 -72.

          -  Patients fulfilling the American College of Rheumatology Clinical and Radiographic
             criteria for Osteoarthritis.

        Exclusion criteria:

          -  Patients younger than 40 years

          -  Women of child bearing potential.

          -  Women either sterilized for more than 3 months, or post-menopausal for more than 12
             months. Menopause is defined as over age of 60 years or being amenorrheic for at least
             2 years with plasma FSH level >30 IU/L.

          -  Secondary osteoarthritis: e.g., autoimmune disease, joint dysplasia, aseptic
             osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease,
             Stickler's syndrome, joint infection, haemophilia, haemochromatosis, calcium
             pyrophosphate deposition disease, or neuropathic arthropathy.

          -  Presence of local skin abnormality at the affected knee joint.

          -  Intra-articular injection within 3 months.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.